{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:03:19Z","timestamp":1793228599103,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prevalence of macrolide-resistant Mycoplasma pneumoniae has increased considerably. Treatment in children has become challenging. This study aimed to evaluate the efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed the data of patients with macrolide-resistant <jats:italic>Mycoplasma pneumoniae<\/jats:italic> pneumonia hospitalized between May 2019 to August 2022. According to treatment, patients were divided into three groups: oral doxycycline treatment alone (DOX group), changed from intravenous azithromycin to oral doxycycline (ATD group), and intravenous azithromycin treatment alone (AZI group). ATD group cases were separated into two sub-groups: intravenous azithromycin treatment&lt;3 days (ATD1 group) and \u2265\u20093 days (ATD2 group). Clinical symptoms were compared in each group and adjusted by Propensity score matching (PSM) analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 106 were recruited in this study. 17 (16%) were in DOX group, 58 (55%) in ATD group, and 31(29%) in AZI group. Compared with ATD group and AZI group, the DOX group showed shorter hospitalization duration and fever duration after treatment, while higher rate of chest radiographic improvement. After using PSM analysis, shorter days to hospitalization duration (<jats:italic>P<\/jats:italic>\u2009=\u20090.037) and to fever duration after treatment (<jats:italic>P<\/jats:italic>\u2009=\u20090.027) in DOX\u2009+\u2009ATD1 group than in ATD2 group was observed. A higher number of patients in the DOX\u2009+\u2009ATD1 group achieved defervescence within 72\u00a0h (<jats:italic>P<\/jats:italic>\u2009=\u20090.031), and fewer children received glucocorticoid adjuvant therapy (<jats:italic>P<\/jats:italic>\u2009=\u20090.002). No adverse reactions associated with doxycycline was observed during treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Children receiving early oral doxycycline had a shorter duration of fever and hospitalization in macrolide-resistant <jats:italic>Mycoplasma pneumoniae<\/jats:italic> patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13052-024-01615-y","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T01:01:47Z","timestamp":1709600507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods"],"prefix":"10.1186","volume":"50","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Ni","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"3","key":"1615_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jiac.2013.09.009","volume":"20","author":"K Izumikawa","year":"2014","unstructured":"Izumikawa K, Izumikawa K, Takazono T, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181\u20135.","journal-title":"J Infect Chemother"},{"issue":"2","key":"1615_CR2","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1128\/AAC.01806-13","volume":"58","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58(2):1034\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1615_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.diagmicrobio.2010.03.004","volume":"67","author":"Y Liu","year":"2010","unstructured":"Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67(4):355\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"1615_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jac\/dks457","volume":"68","author":"N Principi","year":"2013","unstructured":"Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013;68(3):506\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","volume":"7","author":"S Pereyre","year":"2016","unstructured":"Pereyre S, Goret J, B\u00e9b\u00e9ar C. Mycoplasma pneumoniae: current knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016;7:974.","journal-title":"Front Microbiol"},{"issue":"6","key":"1615_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s10156-009-0715-7","volume":"15","author":"K Matsubara","year":"2009","unstructured":"Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380\u20133.","journal-title":"J Infect Chemother"},{"issue":"7","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","volume":"5","author":"K Kim","year":"2022","unstructured":"Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of Macrolide-Resistant Mycoplasma pneumoniae infections: a systematic review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220949.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1615_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1128\/AAC.02060-12","volume":"57","author":"F Zhao","year":"2013","unstructured":"Zhao F, Liu G, Wu J, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57(3):1521\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3345\/kjp.2017.60.6.167","volume":"60","author":"HJ Yang","year":"2017","unstructured":"Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2017;60:167\u201374.","journal-title":"Korean J Pediatr"},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41426-018-0097-y","volume":"7","author":"W Dai","year":"2018","unstructured":"Dai W, Wang H, Zhou Q, et al. The concordance between upper and lower respiratory microbiota in children with Mycoplasma pneumoniae pneumonia. Emerg Microbes Infect. 2018;7:92.","journal-title":"Emerg Microbes Infect"},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11596-020-2261-6","volume":"40","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang Q, Du JL, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with Mycoplasma Pneumoniae Pneumonia. Curr Med Sci. 2020;40:822\u20138.","journal-title":"Curr Med Sci"},{"issue":"12","key":"1615_CR12","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/cid\/cis784","volume":"55","author":"T Okada","year":"2012","unstructured":"Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55(12):1642\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1615_CR13","first-page":"1674","volume":"12","author":"National Health Commission of the People\u2019s Republic of China SAoTCM","year":"2019","unstructured":"National Health Commission of the People\u2019s Republic of China SAoTCM. Guideline for diagnosis and treatment of community acquired pneumoniain children(2019 version). Chin J Clin Infect Dis. 2019;12(1):1674\u20132397.","journal-title":"Chin J Clin Infect Dis"},{"issue":"2","key":"1615_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/INF.0b013e318234597c","volume":"31","author":"YC Hsieh","year":"2012","unstructured":"Hsieh YC, Tsao KC, Huang CG, et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J. 2012;31(2):208\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"1615_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1348-0421.2001.tb01293.x","volume":"45","author":"N Okazaki","year":"2001","unstructured":"Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001;45(8):617\u201320.","journal-title":"Microbiol Immunol"},{"issue":"14","key":"1615_CR16","first-page":"1082","volume":"37","author":"Wang Yacui1 WX","year":"2022","unstructured":"Wang Yacui1 WX. Liu Fang3 YQ, Jieqiong1 L. Epidemiological characteristics and macrolide-resistance of children hospitalized with Mycoplasma pneumoniae infection in Beijing from 2016 to 2019. Chin J Appl Clin Pediatr. 2022;37(14):1082\u20135.","journal-title":"Chin J Appl Clin Pediatr"},{"issue":"3","key":"1615_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1568005054880109","volume":"5","author":"CM B\u00e9b\u00e9ar","year":"2005","unstructured":"B\u00e9b\u00e9ar CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263\u201371.","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"1","key":"1615_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","volume":"16","author":"H Lee","year":"2018","unstructured":"Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther. 2018;16(1):23\u201334.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"1615_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CMR.00114-16","volume":"30","author":"KB Waites","year":"2017","unstructured":"Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and Beyond. Clin Microbiol Rev. 2017;30(3):747\u2013809.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"1615_CR20","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1128\/AAC.01684-08","volume":"53","author":"Y Liu","year":"2009","unstructured":"Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1615_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.21037\/apm.2019.10.05","volume":"8","author":"M Lin","year":"2019","unstructured":"Lin M, Shi L, Huang A, Liang D, Ge L, Jin Y. Efficacy of levofloxacin on macrolide-unresponsive and corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Ann Palliat Med. 2019;8(5):632\u20139.","journal-title":"Ann Palliat Med"},{"issue":"12","key":"1615_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1097\/INF.0b013e3182a25c71","volume":"32","author":"DC Lung","year":"2013","unstructured":"Lung DC, Yip EK, Lam DS, Que TL. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32(12):1396\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"1615_CR23","doi-asserted-by":"crossref","unstructured":"Lee H, Choi YY, Sohn YJ et al. Clinical efficacy of doxycycline for treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children. Antibiot (Basel). 2021;10(2).","DOI":"10.3390\/antibiotics10020192"},{"issue":"2","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1128\/AAC.50.2.709-712.2006","volume":"50","author":"S Suzuki","year":"2006","unstructured":"Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50(2):709\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"1615_CR25","doi-asserted-by":"crossref","unstructured":"Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. 2019;8(5).","DOI":"10.3390\/jcm8050726"},{"issue":"4","key":"1615_CR26","first-page":"315","volume":"19","author":"S Gavrilovic","year":"2019","unstructured":"Gavrilovic S, Andrijevic A, Mujakovic A, Odeyemi Y, Paralija B, Gajic O. Adjunct corticosteroid treatment in patients with pneumonia: a precision medicine approach. Bosn J Basic Med Sci. 2019;19(4):315\u201320.","journal-title":"Bosn J Basic Med Sci"},{"issue":"3","key":"1615_CR27","first-page":"161","volume":"56","author":"HM Song","year":"2018","unstructured":"Song HM. Rational use of glucocorticoids. Zhonghua Er Ke Za Zhi. 2018;56(3):161\u20132.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"4","key":"1615_CR28","doi-asserted-by":"publisher","first-page":"ofv178","DOI":"10.1093\/ofid\/ofv178","volume":"2","author":"NW Carris","year":"2015","unstructured":"Carris NW, Pardo J, Montero J, Shaeer KM. Minocycline as a substitute for doxycycline in targeted scenarios: a systematic review. Open Forum Infect Dis. 2015;2(4):ofv178.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329\u201342.","journal-title":"Clin Ther"},{"issue":"7598","key":"1615_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(69)91787-5","volume":"1","author":"G Forti","year":"1969","unstructured":"Forti G, Benincori C. Doxycycline and the teeth. Lancet. 1969;1(7598):782.","journal-title":"Lancet"},{"issue":"5","key":"1615_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","volume":"166","author":"SR Todd","year":"2015","unstructured":"Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166(5):1246\u201351.","journal-title":"J Pediatr"},{"issue":"2","key":"1615_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0009922806290026","volume":"46","author":"B Volovitz","year":"2007","unstructured":"Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila). 2007;46(2):121\u20136.","journal-title":"Clin Pediatr (Phila)"},{"issue":"10","key":"1615_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","volume":"43","author":"AR S\u00e1nchez","year":"2004","unstructured":"S\u00e1nchez AR, Rogers RS 3rd, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43(10):709\u201315.","journal-title":"Int J Dermatol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-024-01615-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:14:54Z","timestamp":1709928894000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-024-01615-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1186\/s13052-024-01615-y","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"5 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional research ethics committee of the Ningbo Medical Center Lihuili Hospital (Date-11\/18\/2022\/NO-KY2022SL379-01), and was conducted in compliance with ethical principles originating in the Declaration of Helsinki. The ethics committee listed above waived the requirement for informed consent, because this study used currently existing medical records collected during the course of routine medical care and did not pose any additional risks to the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors had no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"38"}}